4-苄基-1-乙基哌啶 | 93803-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-苄基-1-乙基哌啶
• 英文名称: 4-benzyl-1-ethylpiperidine
• 英文别名: 4-benzyl-N-ethylpiperidine
• CAS: 93803-30-6
• 化学式: C₁₄H₂₁N
• mdl: MFCD28049257
• 分子量: 203.327
• InChiKey: ZBKWFCQXPPFOLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-氯丙酰氯 、 4-苄基-1-乙基哌啶 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 3-chloro-1-(4-((1-ethylpiperidin-4-yl)methyl)phenyl)propan-1-one
  参考文献：
  名称：

  Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors

  摘要：

  We have previously reported the discover), and preliminary structure activity relationships of a series of beta-aminoketones that disrupt the binding of coactivators to TR. However, the most active compounds had moderate inhibitory potency and relatively high cytotoxicity, resulting in narrow therapeutic index. Additionally, preliminary evaluation of in vivo toxicology revealed a significant dose related cardiotoxicity. Here we describe the improvement of pharmacological properties of thyroid hormone receptor coactivator binding inhibitors. A comprehensive Survey of the effects of substitutents in key areas of the molecule was carried out based on mechanistic insight from the earlier report. This study revealed that both electron withdrawing and hydrophobic substituents on the aromatic ring led to higher potency. On the other hand, moving from an alkyl to a sulfonyl alkyl side chain led to reduced cytotoxicity, Finally, utilization of airline moieties having low pK(a)'s resulted in lowered ion channel activity without any loss of pharmacological activity.

  DOI：

  10.1021/jm9002704
• 作为产物：
  描述：

  4-苄基哌啶 、 乙醇 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 苯丙氨酸苯胺 、 potassium tert-butylate 作用下， 反应 13.0h， 以85%的产率得到4-苄基-1-乙基哌啶
  参考文献：
  名称：

  借位氢方法在温和条件下钌催化醇与胺的N-烷基化反应

  摘要：

  使用简单的氨基酰胺配体，在宽范围的条件下，用简单的醇进行钌催化的伯胺和仲胺的一锅烷基化。使用醇作为溶剂，即使在低至室温下也可以在温和的条件下实现烷基化。在许多情况下，以高转化率和选择性进行反应。使用化学计量的醇，反应也可以在有机溶剂中在高温下以高选择性进行。

  DOI：

  10.1021/jo501273t

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• Novel agents for preventing and treating disorders involving modulation of the RyR receptors
  申请人：Marks R. Andrew

  公开号：US20070049572A1

  公开（公告）日：2007-03-01

  The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

  本发明提供了Formula I的新化合物及其盐、水合物、溶剂合物、络合物和前药。本发明还提供了合成Formula I化合物的方法。此外，该发明还提供了包含Formula I化合物的药物组合物，以及使用Formula I药物组合物治疗和预防与调节细胞中钙通道功能的RyR受体相关的疾病和疾病的方法。这些疾病包括但不限于心脏疾病、骨骼肌肉疾病、认知障碍和疾病、恶性高热、糖尿病和婴儿猝死综合征。心脏疾病包括但不限于心律不齐疾病、运动诱发的心律不齐疾病、猝死、运动诱发的猝死、充血性心力衰竭、慢性阻塞性肺疾病和高血压。心律不齐疾病和疾病包括运动诱发的心律不齐疾病，但不限于心房和心室心律失常、心房和心室颤动、心房和心室快速心律失常、心房和心室快速心跳、儿茶酚胺多形性心室心动过速（CPVT）及其运动诱发的变体。骨骼肌肉疾病包括但不限于骨骼肌疲劳、运动诱发的骨骼肌疲劳、肌肉萎缩、膀胱疾病和失禁。认知障碍和疾病包括但不限于阿尔茨海默病、各种记忆丧失形式和年龄相关的记忆丧失。
• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210147383A1

  公开（公告）日：2021-05-20

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR 6 R 6 or C═O; Ring A is: and R 1 , R 2 , R 3 , R 4 , R 5 , m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  公开的化合物为Formula (I)的化合物或其盐，其中：Z为CR6R6或C═O；环A为：而R1、R2、R3、R4、R5、m和n在此处有定义。还公开了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面非常有用。
• [DE] ABGEWANDELTE AMINOSÄUREN, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND VERFAHREN ZU IHRER HERSTELLUNG<br/>[EN] MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION<br/>[FR] AMINOACIDES MODIFIES, MEDICAMENTS CONTENANT CES COMPOSES ET LEUR PROCEDE DE PRODUCTION
  申请人：DR. KARL THOMAE GMBH

  公开号：WO1998011128A1

  公开（公告）日：1998-03-19

  (DE) Die vorliegende Erfindung betrifft abgewandelte Aminosäuren der allgemeinen Formel (I), in der A, Z, X, n, m, R, R2, R3, R4 und R11 wie in den Ansprüchen 1 bis 5 definiert sind, deren Tautomere, deren Diastereomere, deren Enantiomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung sowie deren Verwendung zur Erzeugung und Reinigung von Antikörpern und als markierte Verbindungen in RIA- und ELISA-Assays und als diagnostische oder analytische Hilfsmittel in der Neurotransmitter-Forschung.(EN) The invention concerns modified aminoacids of general formula (I) in which A, Z, X, n, m, R, R2, R3, R4 and R11 are defined in claims 1 through 5, their tautomers, their diastereomers, their enantiomers, their mixtures and their salts, specially their physiologically compatible salts with inorganic or organic acids or bases, pharmaceuticals containing these compounds, their use and the method for their production, as well as their use for the production and purification of antibodies and as marked compounds in RIA and ELISA assays and as diagnostic or analytic auxiliary agents in neurotransmitter research.(FR) La présente invention concerne des aminoacides modifiés correspondant à la formule générale (I), dans laquelle, A, Z, X, n, m, R, R2, R3, R4 et R11 correspondent à la définition donnée dans les revendications 1 à 5, ainsi que leurs tautomères, leurs diastéromères, leurs énantiomères, leurs mélanges et leurs sels, en particulier leurs sels physiologiquement compatibles, avec des acides ou des bases inorganiques ou organiques, des médicaments contenant ces composés. L'invention concerne également l'utilisation de ces composés et leur procédé de production, ainsi que leur utilisation pour la production et la purification d'anticorps, comme composés marqués pour effectuer des dosages radio-immunologiques et des tests ELISA, et comme agents auxiliaires de diagnostic et d'analyse dans la recherche relatives aux neurotransmetteurs.

  本发明涉及一般式（I）的改性氨基酸，其中A，Z，X，n，m，R，R2，R3，R4和R11如权利要求1至5中所定义，它们的互变异构体，对映异构体，对映体，混合物和盐，特别是它们与无机或有机酸或碱的生理相容性盐，含有这些化合物的药物，它们的使用和制备方法，以及它们用于抗体的制备和纯化，作为RIA和ELISA测定中标记化合物以及作为神经递质研究中的诊断或分析辅助剂的用途。